Inflammatory cytokines and lipid profile in children and adolescents with nephrotic syndrome receiving L. Plantarum: a randomized, controlled feasibility trial
Fortes, Patrícia Marques; Teles Filho, Ricardo Vieira; Azevêdo, Lucas Henrique Souza de; Queiroz, Victória Coelho Jácome; Costa, Paulo Sérgio Sucasas da.
Rev. Assoc. Med. Bras. (1992)
; 66(11): 1487-1492, Nov. 2020. tab, graf
Artículo
en Inglés
| SES-SP, LILACS | ID: biblio-1143634
SUMMARY This study aimed to evaluate the efficacy of the action of the Lactobacillus Plantarum probiotic as a immunomodulatory and hypolipidemic agent in dyslipidemic nephrotic children and adolescents.
METHODS:
This is a randomized, double-blind, placebo-controlled clinical trial in pediatric, compensated or partially compensated nephrotic syndrome and dyslipidemic subjects undergoing regular outpatient follow-up. Serum lipid and TNF-α (proinflammatory) and IL-10 (anti-inflammatory) cytokine variations were evaluated. Cytokines were analyzed by enzyme-linked immunosorbent assay (ELISA).RESULTS:
In the probiotic group there was a tendency to reduce TNF-α levels and increase IL-10 levels when compared to controls. Regarding the lipid profile, there was a decrease in serum triglyceride (6.0 mg / dL) and total cholesterol (41.5 mg / dL) levels in the probiotic group when compared to baseline levels, while in the control group there was an increase in serum triglyceride (49.5 mg / dL) and total cholesterol (8.0 mg / dL) levels, respectively.CONCLUSION:
Preliminary results suggest that L. Plantarum showed an immunomodulatory and hypolipidemic effect in nephrotic and dyslipidemic pediatric subjects.
Biblioteca responsable:
BR1.1
Texto completo
Documentos relacionados